Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
127.60    2.60 (2.08%)
Bid:
127.60
Ask:
128.40
Spread: 0.80 (0.627%)
Market Cap: £310.60m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

8 May 2026 07:00

RNS Number : 5074D
PureTech Health PLC
08 May 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Briarwood Chase Management LLC

City of registered office (if applicable)

New York

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name

City of registered office

Country of registered office

Morgan Stanley & Co., LLC

New York

USA

5. Date on which the threshold was crossed or reached

06-May-2026

6. Date on which Issuer notified

07-May-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.093400

0.000000

5.093400

12398267

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

12398267

5.093400

Sub Total 8.A

12398267

5.093400%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aalap Mahadevia

5.093400

5.093400%

Briarwood Chase Management LLC

5.093400

5.093400%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-May-2026

13. Place Of Completion

New York, NY USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLARMBTMTBMTLF
Date   Source Headline
28th Aug 20257:00 amRNSHalf-year Report
21st Aug 202512:00 pmRNS-RPureTech Showcases Differentiated IPF Strategy
18th Aug 20257:00 amRNSNotice of Results
13th Aug 20255:12 pmRNS-RPRTC's Vedanta Announces VE202 Phase 2 Results
12th Aug 202512:00 pmRNS-RPRTC Launches Celea to Advance Ph3-Ready IPF Drug
5th Aug 20255:30 pmRNSHolding(s) in Company
1st Aug 20257:00 amRNSTotal Voting Rights
17th Jul 202512:05 pmRNS-RPRTC’s Seaport Begins Phase 2b Study in MDD
16th Jul 20257:00 amRNSPureTech Announces Leadership Transition
8th Jul 20255:45 pmRNSDirectorate Change
4th Jul 20255:30 pmRNSPDMR Notification
4th Jul 20255:30 pmRNSPDMR Notification RSU Vesting
4th Jul 20255:30 pmRNSPDMR Notification RSU Vesting
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20257:00 amRNS-RPRTC'S Vor Announces RemeGen License & $175M PIPE
16th Jun 20255:27 pmRNSResult of AGM
29th May 20255:30 pmRNSHolding(s) in Company
22nd May 202512:00 pmRNS-RPRTC to Present at Jefferies Healthcare Conference
21st May 20257:00 amRNS-RPRTC: IPF Data Support Lung Function Stabilization
9th May 202512:00 pmRNS-RPRTC Publishes Research on Unmet IPF Patient Needs
1st May 202512:00 pmRNS-RPRTC To Present Ph2b IPF Results at ATS Conference
30th Apr 20257:00 amRNSFinal Results
23rd Apr 20257:00 amRNSNotice of Results
11th Apr 20257:00 amRNSHolding(s) in Company
9th Apr 20253:00 pmRNSForm 8.3 PURETECH HEALTH PLC
9th Apr 20257:00 amRNS-RPRTC Appoints Peel Hunt Joint UK Corporate Broker
8th Apr 20252:53 pmGNWInvesco Ltd: Form 8.3 - PureTech Health PLC; Opening Position disclosure
8th Apr 20252:48 pmEQSForm 8.3 - The Vanguard Group, Inc.: PureTech Health plc
8th Apr 20251:15 pmRNSForm 8.3 -PURETECH HEALTH PLC
8th Apr 20251:10 pmRNSForm 8.3 PURETECH HEALTH PLC
8th Apr 202511:40 amGNWForm 8.3 - [PURETECH HEALTH PLC - Opening Disclosure - 07 04 2025] - (CGAML)
8th Apr 202510:00 amRNSForm 8.3 - Puretech Health plc
7th Apr 20255:22 pmRNSRule 2.8 Announcement
7th Apr 20254:27 pmRNSStatement re Possible Offer
11th Mar 202511:05 amRNS-RPRTC's Seaport Adds Finance/Operations Exec to BOD
3rd Mar 20257:00 amRNSTotal Voting Rights
27th Feb 20255:30 pmRNSPDMR Notification RSU Vesting
25th Feb 202512:00 pmRNS-RPRTC Presents at Leerink Partners Healthcare Conf
12th Feb 202512:05 pmRNS-RPRTC's Seaport Publishes New Glyph Platform Data
27th Jan 20257:00 amRNS-RPRTC's Vedanta Publishes Ph2 in Nature Medicine
8th Jan 202512:00 pmRNS-RPureTech to Present at the JP Morgan Conference
6th Jan 20257:00 amRNS-RPureTech Appoints UBS as UK Corporate Broker
16th Dec 20247:00 amRNSPRTC's Ph2b in IPF Successful; New SOC Potential
11th Dec 20245:30 pmRNSHolding(s) in Company
27th Nov 20245:31 pmRNSHolding(s) in Company
27th Nov 20245:30 pmRNSHolding(s) in Company
1st Nov 20247:00 amRNSTotal Voting Rights
31st Oct 20245:00 pmRNSDirector/PDMR Shareholding
21st Oct 20247:00 amRNSPRTC's Seaport Closes $225M Series B Financing
27th Sep 20247:00 amRNSKarXT/Cobenfy Approved by FDA; PRTC Receives $29M

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.